5. The antibody or an antigen-binding fragment thereof as claimed in claim **1**, wherein the antibody or the antigen-binding fragment leads to a reduction in Th17 cell proliferation, Th17 cell differentiation or Th17 cell activity and/or inhibits the formation of antibodies against endogenous antigens by B cells.

6. The antibody or an antigen-binding fragment thereof as claimed in claim **1**, wherein the antigen of the bacterium *Candidatus savagella* is a bacterial wall protein.

7. The antibody or an antigen-binding fragment thereof as claimed in claim **1**, wherein the antibody or the antigen-binding fragment binds to an epitope from the myosin-cross-reactive antigen.

8. A method for producing an antibody as claimed in claim **1**, the method comprising:

a) immunizing chickens with an immunogenic peptide from an antigen of the bacterium *Candidatus savagella*; and

b) recovering and purifying the antibody formed in the chickens or in an egg laid by said chickens.

9. A drug comprising the antibody or an antigen-binding fragment thereof as claimed in claim **1**.

10. A method for prevention or treatment of an oncological disease, an allergic disease, an immune disease or an autoimmune disease, said diseases being mediated by the activity of Th17 cells, the method comprising administering the as claimed in claim **9**.

11. The drug as claimed in claim **10**, wherein the allergic disease, immune disease, or autoimmune disease is selected from the group consisting of multiple sclerosis, type 1 diabetes, rheumatoid arthritis and allergic asthma.

12. The drug as claimed in claim **9**, wherein the antibody or an antigen-binding fragment thereof is configured to be administered orally.

13. The drug as claimed in claim **9**, wherein the antibody or an antigen-binding fragment thereof is configured to be used in combination with an antibiotic.

14. A method for producing a drug as claimed in claim **9**, comprising:

a) producing an antibody or an antigen-binding fragment thereof configured to bind to an antigen of the bacterium *Candidatus savagella* and (i) inhibits the adhesion of the bacterium to intestinal epithelial cells, preferably human intestinal epithelial cells, and/or (ii) depletes the bacterium; and

b) formulating the antibody or an antigen-binding fragment thereof as a drug.

15. A kit comprising an antibody or an antigen-binding fragment thereof as claimed in claim **1**, the kit being configured for reduction of Th17 cell proliferation, Th17 cell differentiation or Th17 cell activity and/or inhibition of the formation of antibodies against endogenous antigens by B cells.

16. The antibody or an antigen-binding fragment thereof as claimed in any of claim **6**, wherein the myosin-cross-reactive antigen comprising the amino acid sequence shown in SEQ ID No. 1.

17. The antibody or an antigen-binding fragment thereof as claimed in claim **7**, wherein the epitope comprises the amino acid sequence SVLDEFYWLDKKDPYSL (SEQ ID No. 2), PDFKAVRFTRRNQYESMI (SEQ ID No. 3), and/or QATSIKILRDGKEEEIKL (SEQ ID No. 4).

18. The method as claimed in claim **8**, wherein the antigen is a bacterial wall protein of the bacterium *Candidatus savagella.*

19. The drug as claimed in claim **13**, wherein the antibiotic is a beta-lactam and/or a glycopeptide antibiotic.

20. A kit as claimed in claim **15**, wherein the kit further comprises an antibiotic.

* * * * *